Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.

The stock option is intended to be an incentive stock option to the extent permitted by law and has an exercise price per share equal to $7.52, the fair market value on the grant date. The stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to Dr. Klassen's continued service relationship with the Company on each such date. This stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

The stock option was granted as an inducement material to Dr. Klassen's entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/18/2013)... MILAN , June 19, 2013 ... in fluctuating Parkinson,s disease (PD) patients as add-on ... clinically important improvement in motor symptoms in fluctuating ...   Newron Pharmaceuticals S.p.A. ("Newron"), a ... and pain therapies, and its partner Zambon S.p.A., ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6
... 2011 Asante Solutions, Inc. (Asante), a medical device ... the CE mark for its Pearl Insulin Pump, the ... The CE mark is a European proof of conformity ... environmental requirements. Asante has begun discussions with potential distribution ...
... 12, 2011 PRA International, a leading Clinical Research Organization, ... (SRM) group will speak at the World Drug Safety Congress ... will also host an exhibit at booth #2. ... chair the first breakout stream, "Operational Safety," on 13 April ...
Cached Medicine Technology:Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2PRA International Experts to Speak at Drug Safety Conference 2
(Date:6/19/2013)... years, Alzheimer,s researchers have focused on two proteins that ... may contribute to the disease: plaques made up of ... tau. , But for the first time, an Alzheimer,s ... independently, but at the interaction of the two proteins ... post-mortem Alzheimer,s patients and in mouse brains with Alzheimer,s ...
(Date:6/19/2013)... that the incidence of cancer is many fold higher ... have an inadequate understanding on how best to treat ... are occasionally included in clinical trials, those elderly patients ... patients. Thus, the broader elderly patient population is not ... the Elderly Task Force is now starting a new ...
(Date:6/19/2013)... IL (PRWEB) June 19, 2013 Chicago is ... the 31st, 48th and 50th Chicago Wards will require landlords ... – or face fines. The ordinance also makes ... complying with all treatment requests – which often include disposing ... pest control company Orkin reported that it did more bed ...
(Date:6/19/2013)... The Cancer Support Community (CSC), an international nonprofit organization, ... whole patient with the launch today of the Cancer ... event, held at the Newseum, will feature a keynote ... members who have made a significant impact on cancer ... engaged in the cancer journey. , ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 A brain ... for those closest to them. The sudden onset of ... brain tumor has on a patient’s behavioral and cognitive ... both the patient and family. The American Brain ... July 26 and Saturday, July 27 in Chicago, focuses ...
Breaking Medicine News(10 mins):Health News:New Alzheimer's research suggests possible cause: The interaction of proteins in the brain 2Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Chicago Ordinance Requires Landlords and Tenants to Take Responsibility for Bed Bugs 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 2Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 3
... 2, 2010 As part of a national clinical ... in effectiveness between two popular treatments for one of ... incontinence. Stress incontinence affects up to 50 percent ... their lives. Women with stress incontinence experience leakage during ...
... PeriGen, ... clinical and financial value, today announced that Donald A. Deieso, Ph.D., the Company’s Chairman ... 2010 Award in New Jersey. , ... Princeton, NJ -- PeriGen, Inc. , the only OB-specific risk ...
... has received the human papillomavirus (HPV) vaccine to help prevent ... Washington University School of Medicine in St. Louis. The ... American Journal of Preventive Medicine . The HPV vaccine ... of which are found in about 70 percent of all ...
... Healthcare reform -- and the many options for fixing a broken ... According to an article in the June issue of the ... many who suffer from disabling arthritis of the hip and knee, ... crisis to medical care. "This is not a just a ...
... if young adults were more fit, 34% of high blood ... News) -- Low levels of physical activity and fitness significantly ... study of young adults shows. , The study, released online ... issue of the journal Hypertension , found that about ...
... have paired up to create technology that has ... the first procedure-based, hands-on surgical training software. Their ... surgeons through real-time operative procedures using the Robotic ... MD, a staff physician in Urology at Roswell ...
Cached Medicine News:Health News:UT Southwestern investigators perform head-to-head comparison of incontinence treatments 2Health News:Donald A. Deieso, Ph.D., Chairman & CEO, PeriGen, Inc. Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist 2Health News:Donald A. Deieso, Ph.D., Chairman & CEO, PeriGen, Inc. Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist 3Health News:One-third of young girls get HPV vaccine to prevent cervical cancer 2Health News:One-third of young girls get HPV vaccine to prevent cervical cancer 3Health News:Health-care economics and policy: It's a perfect storm 2Health News:Health-care economics and policy: It's a perfect storm 3Health News:Being Young and Sedentary Raises Hypertension Risk Later 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 3Health News:Surgeon-engineer team produce training software for robot-assisted surgery 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: